Skip to content

Evaluation of the efficacy and safety of Policosanol-Sugarcane Wax Alcohols in improving cognitive function

A 12-week, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Policosanol-Sugarcane Wax Alcohols for the improvement of cognitive function

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0012223
Enrollment
72
Registered
2026-07-03
Start date
2026-07-03
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(Health Functional Food) : At Visit 1, participants who provide written informed consent will be assessed for eligibility according to the inclusion and exclusion criteria. At Visit 2, eligible

Sponsors

Ewha Womans University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Those who agree to participate in this study before the test begins and submit a completed informed consent form 2) Men and women aged 55 to under 80 years old 3) Those who complain of subjective cognitive decline

Exclusion criteria

Exclusion criteria: 1) Individuals suspected of having dementia as a result of a neuropsychological examination 2) Those diagnosed with any Axis I psychiatric disorder 3) Those with major medical or surgical diseases requiring immediate treatment, according to their medical history, physical examination, neurological examination, or laboratory tests 4) Individuals with contraindications to MRI 5) Individuals with the following diseases: ? Malignant tumors, severe cerebrovascular disease, heart disease, or neuropsychiatric disorders requiring treatment ? A history of traumatic brain injury accompanied by loss of consciousness or convulsions within the past six months ? A history of acute stroke within the last three months ? Uncontrolled hypertension, diabetes, thyroid dysfunction, or kidney failure ? Severe hearing or vision impairment that makes functional evaluation impossible 6) Individuals who have taken anti-dementia drugs or brain metabolism enhancers in the past month 7) Those who have taken psychotropic drugs within the past month 8) Those who have taken any drug or health functional food affecting cognitive function, or foods similar to the test material within the past month 9) Those who have participated in other clinical trials (including human trials) within the past month 10) Those with hypersensitivity to the ingredients in the investigational products or a history of severe allergic reactions 11) Individuals whom the principal investigator deems unsuitable for participation due to other reasons

Design outcomes

Primary

MeasureTime frame
Cambridge Neuropsychological Test Automated Battery (CANTAB)

Secondary

MeasureTime frame
Neuropsychological test and cognitive functional questionnaire;Brain imaging;Safety-related indicators (vital signs, laboratory tests, adverse event)

Countries

Korea, Republic of

Contacts

Public ContactSuji Lee

Ewha Womans University

suji.j.lee@gmail.com+82-2-3277-6708

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Jul 23, 2026